DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR VALPROATE SODIUM
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
All Clinical Trials for Valproate Sodium
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000439 | Drug Treatment for Alcoholics With Bipolar Disorder | Completed | University of Pittsburgh | Phase 2 | 2000-10-01 | The purpose of this study is to test the effectiveness of sodium valproate (Depacon) in treating individuals with alcohol dependence and comorbid bipolar disorder. |
| NCT00000439 | Drug Treatment for Alcoholics With Bipolar Disorder | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | 2000-10-01 | The purpose of this study is to test the effectiveness of sodium valproate (Depacon) in treating individuals with alcohol dependence and comorbid bipolar disorder. |
| NCT00001482 | New Drugs in the Treatment of Mood Disorders | Completed | National Institute of Mental Health (NIMH) | Phase 2 | 1995-05-01 | This clinical study compares the effectiveness of two anticonvulsants Lamotrigine (Lamictal) Monotherapy and Gabapentin (Neurontin) in patients with treatment resistant affective disorders. We initially have found that the response rate to lamotrigine (51%) exceeded that of gabapentin (28%) or placebo (21%). In this study the placebo phase has been dropped so that we examine possible clinical and biological factors predictors of response. The drugs will be given in a randomized order for six weeks each and you will not know when you are on a given one. There will be a 2-4 week "washout" period between treatments. If you respond well to one of these treatments, a longer open continuation period will be offered at the end of this study. This would involve one or both drugs in combination. A variety of rating scales and brain imaging procedures will also be offered before and during each drug evaluation. Both lamotrigine and gabapentin are generally well tolerated. A serious potentially life threatening rash occurs in about 1/500 patients treated with lamotrigine, however. Common side effects are rash, dizziness, unsteadiness, double vision, blurred vision, nausea, vomiting, insomnia, sedation, and headache. These side effects are usually mild, and resolve with continued time on the drug or a decrease in dosage. |
| NCT00004817 | Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures | Completed | Harborview Injury Prevention and Research Center | Phase 3 | 1991-02-01 | OBJECTIVES: I. Determine whether treating head injured patients with valproate sodium will reduce the risk of developing seizures as a result of the head injury. II. Determine the safety of valproate, the appropriate dose, and the effect valproate may have on the recovery of the brain's ability to compute numbers, solve problems, remember information, and control the movement of limbs after head injury. |
| NCT00004817 | Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 3 | 1991-02-01 | OBJECTIVES: I. Determine whether treating head injured patients with valproate sodium will reduce the risk of developing seizures as a result of the head injury. II. Determine the safety of valproate, the appropriate dose, and the effect valproate may have on the recovery of the brain's ability to compute numbers, solve problems, remember information, and control the movement of limbs after head injury. |
| NCT00136110 | Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis | Completed | Princess Beatrix Muscle Foundation | Phase 3 | 2005-04-01 | The purpose of this study is to determine whether the use of sodium valproate is effective in slowing the disease progression in Amyotrophic Lateral Sclerosis. |
| NCT00136110 | Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis | Completed | UMC Utrecht | Phase 3 | 2005-04-01 | The purpose of this study is to determine whether the use of sodium valproate is effective in slowing the disease progression in Amyotrophic Lateral Sclerosis. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Valproate Sodium
Condition Name
Clinical Trial Locations for Valproate Sodium
Trials by Country
Clinical Trial Progress for Valproate Sodium
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Valproate Sodium
Sponsor Name
